avacincaptad pegol
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Trial Timeline
Sep 26, 2022 → Apr 10, 2025
NCT ID
NCT05536297About avacincaptad pegol
avacincaptad pegol is a phase 3 stage product being developed by Astellas Pharma for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT05536297. Target conditions include Geographic Atrophy, Age-Related Macular Degeneration.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06970665 | Approved | Recruiting |
| NCT05536297 | Phase 3 | Completed |
| NCT02686658 | Phase 2/3 | Completed |
| NCT02397954 | Phase 2 | Completed |
| NCT00950638 | Phase 1 | Completed |
| NCT00709527 | Phase 1 | Completed |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| FWY003 + Placebo | Novartis | Phase 2 | 52 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |